Shots:
- Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization
- Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms, lead candidates & BioMarin will advance them into preclinical & clinical development
- AI workbench enables rapid exploration of novel targetable mechanisms & therapeutic candidates, it combines deep learning, automation, advanced biomedical knowledge & massive amounts of in vitro & in vivo data to accurately identify targetable molecular mechanisms & guide the discovery & development of oligonucleotide therapies
Click here to read full press release/ article | Ref: BioMarin | Image: BioMarin
The post BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence first appeared on PharmaShots.
